Jim Cramer's Stop Trading: Does Agios Pharmaceuticals Have a Monumental Cancer Treatment?

NEW YORK (TheStreet) -- Agios Pharmaceuticals (AGIO) may have one of the first big breaks in cancer treatment that doesn't involve chemotherapy, according to TheStreet's Jim Cramer. 

On CNBC's "Cramer's Stop Trading" segment, the co-manager of the Action Alerts PLUS portfolio said November seems too early for the company to reveal its results for Phase 1 testing of the drug, AG-120.

It seems too early, unless of course, the company has something that is going to be monumental in the future, Cramer added. 

He noted that Celgene (CELG) has the marketing rights to the drug and also a large stake in Agios Pharmaceuticals.


-- Written by Bret Kenwell in Petoskey, Mich.

Follow @BretKenwell

At the time of publication, Cramer's Action Alerts PLUS had no position in companies mentioned.

More from Opinion

AAP Exclusive: Cramer Says The President is No Longer on the Side of the Bulls

AAP Exclusive: Cramer Says The President is No Longer on the Side of the Bulls

Why It Makes Perfect Sense for Netflix and Amazon to Buy Up Movie Theaters

Why It Makes Perfect Sense for Netflix and Amazon to Buy Up Movie Theaters

2 More Reasons to Sell All Your Stocks and Run Away

2 More Reasons to Sell All Your Stocks and Run Away

Sean Hannity's Link to Trump Lawyer Raises Questions: Doug Kass Insider

Sean Hannity's Link to Trump Lawyer Raises Questions: Doug Kass Insider

Netflix Blowout Earnings Remind Investors of One Thing: This Company Is a Beast

Netflix Blowout Earnings Remind Investors of One Thing: This Company Is a Beast